Drugs / ASP8232
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02218099 | Sep 2013 → Sep 2014 | chronic kidney disease, type 2 diabetes mellitus | Astellas Pharma Europe B.V. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT02358096 | Mar 2015 → Oct 2016 | chronic kidney disease, type 2 diabetes mellitus | Astellas Pharma Europe B.V. | Completed | No outcome recorded |
| Phase 2 | NCT02302079 | Jan 2015 → Aug 2016 | diabetes mellitus, diabetic macular edema | Astellas Pharma Europe B.V. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASP8232 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02302079 ↗ |
| Action | Inhibit | “ASP8232 is a potent and specific small molecule vascular adhesion protein-1 (VAP-1) inhibitor.” PMID 31388454 ↗ Aug 2019 |
| Modality | Small molecule | “ASP8232 is a potent and specific small molecule vascular adhesion protein-1 (VAP-1) inhibitor.” PMID 31388454 ↗ Aug 2019 |
| Route | Oral | “single oral dose of ASP8232” NCT02218099 ↗ |